Search…
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Search...
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Home
>
Latest
Lates News
20/08/2025
Reserve Bank of New Zealand Governor Hawksby: The fiscal outlook indicates that government spending will decrease, which will help alleviate inflation.
Latest
2 m ago
U.S. massive data center provider Vantage Data Centers announced on Tuesday that it will invest over $2.5 billion in developing a data center campus called "Frontier" in Shackelford County, Texas. The campus is planned to accommodate 10 data centers with a total capacity of 1.4 gigawatts, and is expected to employ over 5,000 staff during construction and operation. The project has already begun construction, with the first building expected to be delivered in the second half of 2026.
3 m ago
According to AI Express News, Postal Securities released a research report on August 20th, giving a buy rating to Beixin Building Materials (000786.SZ). The rating reasons mainly include: 1) Gypsum board demand is under pressure, while paint achieves high growth; 2) Cost rate slightly increased, operating cash flow decreased year-on-year. (Daily Economic News)
6 m ago
On August 20, Novartis announced that its innovative product Nuralda (Arquerant hydrochloride tablets) has been approved by the National Medical Products Administration for the reduction of proteinuria in adult patients with primary IgA nephropathy who are at risk of rapid disease progression. It is reported that Nuralda is the first non-immunological therapy approved in China for the treatment of IgA nephropathy. It is also the first and currently the only highly selective endothelin A (ETA) receptor antagonist for this indication in the country.
6 m ago
Novartis' innovative drug Nolasiban has been approved for the treatment of IgA nephropathy in China.
6 m ago
Britain's inflation accelerates and hits an 18-month high, central bank may reconsider interest rate cuts
See all latest